Emerald Health Stock Falls On Earnings

Emerald Health Therapeutics, Inc. (OTCQX: EMHTF) reported financial results for the quarter and year ending  December 31, 2019. Net sales were $20.3 million in 2019 versus $1.9M in 2018. The company reported a staggering net loss of $111.9 million in 2019, which it said was impacted by a non-cash impairment charge of $65 million related to the Verdélite production facility in Quebec. The stock fell over 6% on the news.

In addition to that charge, $14 million non-cash loss related to the settlement of outstanding issues related to the Pure Sunfarms joint venture, and a $6 million inventory write-down.

Fourth Quarter

Net sales for the fourth quarter were $4.3 million, an increase of 340% from the same period in 2018. The net loss for the quarter was $90 million

“In the second half of 2019 and through the beginning of 2020, our focus has been to cut costs, scale-up commercial production in our two wholly-owned cultivation facilities, and continue our progress toward positive cash flow and profitability,” said Riaz Bandali, President and Chief Executive Officer of Emerald. “We have four distinct assets encompassing cultivation, post-harvest processing, and product development based on science and unique intellectual property.”

Pure Sunfarms

The company has restructured its commitments and relationship with its joint venture, Pure Sunfarms, and its joint venture partner, Village Farms, resulting in the termination of all supply agreements and related obligations. Emerald retains 41.3% ownership and 3 of 6 board seats in Pure Sunfarms. Emerald recognized $19.6 million in a net gain as its share of the joint venture’s net earnings for 2019.

The net sales for Pure Sunfarms consisted entirely of dried cannabis, for the year and fourth quarter of 2019 were $82.8M and $12.1M, respectively, compared to $4.9M and $4.7M in 2018. The gross revenue for Pure Sunfarms fell by 45% sequentially to $13.5 million in the fourth quarter from $24.8 million in the third quarter.

Other Business

In the fourth quarter, Emerald fulfilled its first shipment of premium cannabis products to the Nova Scotia Liquor Corporation for the adult-use market. This first shipment consisted of Emerald’s high potency SYNC 25 CBD oil and dry cannabis flower, bringing distribution to 10 provinces and territories.

Medical sales continued to grow quarter over quarter, with our patient base almost doubling to 5000 since the beginning of the year. Sales grew 85% from the previous year.

One comment

  • TedOliver,Calgary

    May 14, 2020 at 7:44 pm

    I have been heavily invested in EMH for 4 yrs,therefore am expecting better business decisions now that the rif with Valley Farms (own it too) is over,and hopefully the huge losses were a learning experience, and profits will increase substantially this year and the future.They must if current management is to remain.


Leave a Reply

Your email address will not be published. Required fields are marked *

Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 11 hours

$GRAMF Parent Company Buys Jayden’s Journey Dispensary

@GreenMarketRpt – 1 day

Are you ready for your ?? August 2, 2021

Back to Top